Infection ViralNOSOGRIPPENCT05712759
Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period
An observational study of Infection Viral, run by Hospices Civils de Lyon.
Trial summary
Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay. The incidence of laboratory confirmed HAI has been reported rarely. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infection Viral
- What is being tested?
- Influenza-like illness group
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 9 Mar 2025to 9 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any volunteer adult patient (≥ 18 years of age) hospitalized at Edouard Herriot Hospital for at least 24 hours on a study unit, who had a nasopharyngeal swab taken as part of care for the purpose of diagnosing influenza by PCR testing and who had an influenza-like illness meeting the following definition
Who may be able to join
- Any volunteer adult patient (≥ 18 years of age) hospitalized for at least 24 hours on a study unit, who had a nasopharyngeal swab taken as part of care for the purpose of diagnosing influenza by PCR testing and who had an influenza-like illness meeting the following definition:
- Fever greater than 37.8°C in the absence of antipyretics; And/or
- Cough or pharyngeal pain.
Who cannot join
- Any person who does not meet the above definition or who has expressed opposition.
About this study
Official title: Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France
Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay. The incidence of laboratory confirmed HAI has been reported rarely. The proportion of HAI among influenza cases was 11.38% (95% Confidence Interval: 5.19%-19.55%) in a meta-analysis of 14 studies. In France, a prospective surveillance study of adults with Influenza-Like Illness (ILI) over 11 years, reported that 35.6% of the influenza cases diagnosed at hospital were hospital-acquired.
HAI is transmitted via respiratory droplets and by hand contacts. The spread is facilitated by Health Care Professionals (HCPs), patients and visitors.
Read more
Prevention and control of HAI is of upmost importance to preserve patient safety and limit the related economic costs. While vaccination of HCPs has been shown to contribute to the reduction of HAI, less is known on the impact of patient vaccination on the risk of HAI during hospitalization.
The aim of this study is to describe the hospital-acquired influenza in a french university hospital.
- Conditions
- Infection Viral
- Being tested
- Influenza-like illness group
- Keywords
- influenza, hospital, nosocomial
- Medical subject headings
- Virus Diseases, Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Influenza-like illness groupOther
Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.
ILI is defined by fever > 37,8°C or/and cough or sore throat.
What is being measured
The primary outcome is the main question the study is designed to answer.
To describe and document cases of nosocomial influenza occurring at Edouard Herriot Hospital.
The primary endpoint will be assessed by the proportion of patients with nosocomial influenza among all patients with influenza-like illness during an influenza season.
Measured: At inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2023
- Study start9 Mar 2025
- Primary completion9 Mar 2025
- Study completion9 Mar 2025
Why it stopped: change of study design
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infection ViralStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05712759
- Sponsor's protocol ID
- 69HCL22_1064
- Acronym
- NOSOGRIPPE
- Status last verified
- Mar 2025
- First submitted
- 26 Jan 2023
- Last updated
- 11 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France
- ClinicalTrials.gov ID
- NCT05712759
- Acronym / sponsor ID
- NOSOGRIPPE / 69HCL22_1064
- Conditions
- Infection Viral
- Keywords
- influenza, hospital, nosocomial
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: change of study design
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 9 Mar 2025 (actual)
- Primary completion
- 9 Mar 2025 (actual)
- Study completion
- 9 Mar 2025 (actual)
- First posted
- 3 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay. The incidence of laboratory confirmed HAI has been reported rarely. The proportion of HAI among influenza cases was 11.38% (95% Confidence Interval: 5.19%-19.55%) in a meta-analysis of 14 studies. In France, a prospective surveillance study of adults with Influenza-Like Illness (ILI) over 11 years, reported that 35.6% of the influenza cases diagnosed at hospital were hospital-acquired.
HAI is transmitted via respiratory droplets and by hand contacts. The spread is facilitated by Health Care Professionals (HCPs), patients and visitors.
Prevention and control of HAI is of upmost importance to preserve patient safety and limit the related economic costs. While vaccination of HCPs has been shown to contribute to the reduction of HAI, less is known on the impact of patient vaccination on the risk of HAI during hospitalization.
The aim of this study is to describe the hospital-acquired influenza in a french university hospital.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Any volunteer adult patient (≥ 18 years of age) hospitalized at Edouard Herriot Hospital for at least 24 hours on a study unit, who had a nasopharyngeal swab taken as part of care for the purpose of diagnosing influenza by PCR testing and who had an influenza-like illness meeting the following definition
Key inclusion criteria (3 listed)
- Any volunteer adult patient (≥ 18 years of age) hospitalized for at least 24 hours on a study unit, who had a nasopharyngeal swab taken as part of care for the purpose of diagnosing influenza by PCR testing and who had an influenza-like illness meeting the following definition:
- Fever greater than 37.8°C in the absence of antipyretics; And/or
- Cough or pharyngeal pain.
Key exclusion criteria (1 listed)
- Any person who does not meet the above definition or who has expressed opposition.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Influenza-like illness groupEach patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing. ILI is defined by fever > 37,8°C or/and cough or sore throat. | Other | – |
Primary outcome
To describe and document cases of nosocomial influenza occurring at Edouard Herriot Hospital.
Time frame: At inclusion
The primary endpoint will be assessed by the proportion of patients with nosocomial influenza among all patients with influenza-like illness during an influenza season.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2025.
Related trials for Infection Viral
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Infection Viral, run by Hospices Civils de Lyon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To describe and document cases of nosocomial influenza occurring at Edouard Herriot Hospital. (time frame: At inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2025; AzTrials last refreshed its copy on 9 Nov 2026.